IMM 4.92% 32.0¢ immutep limited

Ann: Immutep to present AIPAC Overall Survival data at SABCS 2020, page-13

  1. 601 Posts.
    lightbulb Created with Sketch. 839
    No recent updates from EOC.
    Merck new trial:
    NSCLC combo trial data (Pembro with checkpoint - CTLA -'Quavonlimab').
    Phase 1/2 - ORR - 37.5% and PFS 7.8 months
    Compared to Pembro and Efti in NSCLC - ORR - 53% and PFS 11.8 months
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
32.0¢
Change
0.015(4.92%)
Mkt cap ! $464.8M
Open High Low Value Volume
30.0¢ 32.5¢ 30.0¢ $1.168M 3.702M

Buyers (Bids)

No. Vol. Price($)
5 148547 32.0¢
 

Sellers (Offers)

Price($) Vol. No.
32.5¢ 51809 2
View Market Depth
Last trade - 16.10pm 24/07/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.